The clinical landscape for DLL3-targeted therapies in SCLC is rapidly evolving, with numerous trials underway to evaluate their safety profiles, efficacy, and optimal integration into treatment paradigms. The gene discussed is DLL3; the disease is small cell lung carcinoma.